No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 0.3x · 10Y median 0.3x · 48th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:20:56.017Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T13:20:56.017Z. Latest historical point 2023-05-12.
The latest delayed quote for Biofrontera Inc. (BFRI) stock was $0.89 as of Oct 5, 2026, 4:00 PM EDT, down 12.23% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -16.7% · 3-year avg -52.9%/yr
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Medical - Pharmaceuticals · Woburn, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2023-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.22
Revenue Est.
$8.25M
Last Quarter Results
EPS
$-0.05
vs Estimate
$-0.04
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1BFRI | $11.41M | $0.89 | -12.23% | -16.67% | N/A | N/A | N/A |
| 2ADIL | $11.42M | $4.35 | +5.58% | -56.33% | -71.86% | N/A | vs BFRI |
| 3KPRX | $11.21M | $2.53 | -1.17% | -7.96% | -67.06% | -55.97% | vs BFRI |
| 4BFRG | $11.01M | $0.59 | -3.81% | -58.58% | N/A | N/A | vs BFRI |
| 5IRIX | $11.94M | $0.69 | +7.28% | -42.35% | -38.13% | -26.14% | vs BFRI |
| 6GDTC | $11.95M | $1.01 | +9.78% | -49.59% | N/A | N/A | vs BFRI |
forward FY estimate
N/A
$12.00M
vs Estimate
$9.50M
Consensus Rating
Based on 2 analysts
Average Price Target
$6.00
+573.5% upside
Low
$3.00
Current
$0.89
High
$9.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Quarter ending Dec 2026 | $0.23 | $0.23 | $0.24 | 1 |
| Quarter ending Mar 2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Quarter ending Jun 2027 | $-0.03 | $-0.03 | $-0.03 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.39 | $-0.39 | $-0.39 | 1 |
| FY 2027 | $0.20 | $0.20 | $0.20 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $8.25M | $8.25M | $8.25M | 1 |
| Quarter ending Dec 2026 | $15.80M | $15.80M | $15.80M | 1 |
| Quarter ending Mar 2027 | $11.00M | $11.00M | $11.00M | 1 |
| Quarter ending Jun 2027 | $10.50M | $10.50M | $10.50M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $45.73M | $46.15M | $46.56M | 1 |
| FY 2027 | $52.99M | $53.47M | $53.95M | 1 |
